In CDAA (choline-deficient l-amino acid-defined) diet-induced mouse model of NAFLD, RIPK3 deletion ameliorates liver inflammation and fibrosis but increases liver steatosis [158]. Here, RIPK3 is linked to metabolic dysfunction-associated steatotic liver disease.